Interferon gamma-inducible protein 16 in primary Sjögren’s syndrome: a novel player in disease pathogenesis?

Alessia Alunno†, Valeria Caneparo†, Francesco Carubbi, Onelia Bistoni, Sara Caterbi, Elena Bartoloni, Roberto Giacomelli, Marisa Gariglio, Santo Landolfo and Roberto Gerli*

Abstract

Introduction: There is evidence that interferon is involved in the pathogenesis of primary Sjögren’s syndrome (pSS). The interferon-inducible IFI16 protein, normally expressed in cell nuclei, may be overexpressed, mislocalized in the cytoplasm and secreted in the extracellular milieu in several autoimmune disorders. This leads to tolerance breaking to this self-protein with consequent development of anti-IFI16 antibodies. The aim of this study was to identify the pathogenic and clinical significance of IFI16 and anti-IFI16 in pSS.

Methods: IFI16 and anti-IFI16 were assessed in the serum of 67 pSS patients and over 100 healthy donors by enzyme-linked immunosorbent assay. IFI16 was also evaluated by immunohistochemistry in minor salivary glands of 15 pSS patients and 10 subjects with sicca symptoms but without any clinical, serological or histological features of pSS.

Results: pSS patients display higher serum levels of both IFI16 and anti-IFI16 compared to healthy donors. IFI16 concentration was directly correlated with disease duration and focus score and inversely correlated with age at diagnosis. Moreover, IFI16 positivity was associated with concurrent positivity for rheumatoid factor. Interestingly, the direct correlation between IFI16 positivity and focus score was independent of disease duration and age at diagnosis. pSS minor salivary glands display marked expression and cytoplasmic mislocalization of IFI16 by acinar and ductal epithelial cells as well as infiltrating lymphocytes and peri/intralesional endothelium compared to minor salivary glands with normal architecture or nonspecific chronic sialadenitis. Within the mononuclear cell infiltrate, IFI16 expression appears to parallel the distribution of T lymphocytes.

Conclusion: Our data suggest that the IFI16 protein may be involved in the pathogenesis of glandular inflammation occurring in pSS.
In particular, increased production of IFNs and marked upregulation of type I IFN-regulated gene transcripts, described in pSS patients as well as in animal models of the disease, suggest a strong response due to glandular apoptosis and toll-like receptor activation [5–7]. In this context, the interferon gamma-inducible protein 16 (IFI16), a member of the HIN200/Ifi200 family of IFN-inducible genes, has been drumming up growing interest for its possible role in initiation and progression of chronic inflammatory autoimmune disorders. IFI16 is constitutively expressed in the nucleus of hematopoietic cells, particularly lymphocytes, vascular endothelial cells and keratinocytes [8]. Although it is a multifaceted protein involved in cell cycle regulation, tumor suppression, endothelial cell apoptosis and DNA damage signaling [9–12], great interest is derived from the evidence that its overexpression may drive early steps of an inflammatory response through nuclear factor-kB-mediated secretion of pro-inflammatory molecules. In this context, it is important to note that IFI16, normally expressed in cell nuclei, may be overexpressed in several autoimmune disorders. Its overexpression, cytoplasmic mislocalization and extracellular appearance during cell death lead to the breaking of tolerance to this self-protein with consequent development of anti-IFI16 antibodies [13]. Therefore, the release of IFI16 in the extracellular milieu may mark the first step in the development of autoimmunity [14]. The presence of significant levels of extracellular IFI16 protein and anti-IFI16 antibodies have been recently identified in the sera of patients affected by different systemic autoimmune diseases, including pSS [10, 12, 15–17], thereby confirming its presence in the extracellular milieu and its possible role as an autoantigen [14]. Taken together, these data provide evidence for a novel alarmin function of IFI16 protein which can be overexpressed upon inflammatory stimuli and released in the extracellular environment with eventual endothelial cell binding causing tissue damage. However, a number of questions regarding the role of IFI16 are still open. Thus, we were prompted to analyze possible pathogenic, diagnostic and prognostic significance of IFI16 protein and anti-IFI16 antibodies in patients with pSS, a combined model of systemic autoimmune and chronic inflammatory disorder.

Methods

Patients

Sixty-seven consecutive female patients with pSS, classified according to the European–American criteria [18], with a mean age of 59 years (standard error of the mean (SEM) = 1.5) were enrolled. At the time of enrollment, serum samples were collected and stored at −20 °C until use and clinical and serological features were recorded. Concerning hematological abnormalities, leukopenia was defined as ≤3000 leukocytes/mL, hypergammaglobulinemia was defined as an IgG level over 16 g/L and hypocomplementemia was defined by a reduction of C4 or C3. One-hundred and eighty two healthy blood donors, 145 females and 37 males, with a mean age of 51 years (SEM = 1.2) acted as controls (healthy donors; HDs). Fifteen pSS MSGs, collected at the time of diagnosis, were also retrospectively evaluated. Ten MSGs obtained from subjects with sicca symptoms, but without any clinical and serological features of pSS, acted as controls (five normal MSGs and five showing different grades of non-specific chronic sialadenitis (NSCS), without FLS). The whole study was approved by the local Ethics Committee (Comitato Etico delle Aziende Sanitarie dell’Umbria, CEAS) and written informed consent was obtained in accordance with the declaration of Helsinki.

Determination of extracellular IFI16 protein by capture ELISA

A capture enzyme-linked immunosorbent assay (ELISA) was employed for determination of circulating extracellular IFI16 protein following a procedure detailed elsewhere [15]. Briefly, polystyrene micro-well plates (Nunc-Immuno MaxiSorp; Nunc, Roskilde, Denmark) were coated with a home-made polyclonal rabbit-anti-IFI16 antibody (aa 478–729). Subsequently, the plates were washed and free binding sites were saturated with phosphate-buffered saline (PBS)/0.05 % Tween/3 % bovine serum albumin (BSA). After blocking, sera were added in duplicate. Purified 6His-IFI16 protein was used as standard. BSA served as negative control. The samples were washed and in each case monoclonal mouse anti-IFI16 antibody (Santa Cruz, sc-8023) was added and incubated for 1 h at room temperature. After washing, horseradish peroxidase-conjugated anti-mouse antibody (GE Healthcare Europe GmbH, Milan, Italy) was added. Following the addition of the substrate (TMB; KPL, Gaithersburg, MD, USA), absorbance was measured at 450 nm using a microplate reader (SpectraCount, Packard, Packard BioScience Company). The determination of the concentration was carried out using a standard curve for which increasing concentrations of purified 6His-IFI16 were used.

Determination of antibody titers towards human recombinant IFI16 by ELISA

To detect anti-IFI16 antibodies, polystyrene micro-well plates (Nunc-Immuno MaxiSorp; Nunc) were coated with a solution of recombinant IFI16 in PBS and, after blocking, sera were added in duplicate. After washing, horseradish peroxidase-conjugated rabbit anti-human IgG (Dako Cytomation, Carpinteria, CA, USA) was added. Following the addition of the substrate (TMB; KPL), absorbance was measured at 450 nm using a microplate reader (SpectraCount, Packard). The background reactivity of
the reference mixture was subtracted to calculate the results. A standard curve was constructed by serially diluting IgG from an anti-IFI16-positive patient serum [16, 17].

**Histological analysis of MSG biopsies**

Labial MSG specimens were obtained from 15 pSS patients and 10 HDs according to international guidelines. All sections were randomly analyzed by two expert observers, blinded to clinical and laboratory data. Each sample was independently evaluated and any discrepancies were resolved by consensus. The histological pattern (normal, NSCS, FLS) was assessed using hematoxylin-eosin stained sections [19, 20]. FLS pattern, which is diagnostic for pSS, is characterized by the presence of at least one focus, namely an aggregate of at least 50 lymphocytes, in the glandular tissue. NSCS pattern is characterized by scattered lymphocyte aggregates that do not reach the number of 50 cells and therefore cannot be classified as foci.

Both cellular infiltrate and lymphoid organization, including the presence of GC-like structures, were assessed by immunofluorescence staining of sequential sections with monoclonal antibodies recognizing CD3, CD20 and CD21 (all provided by DakoCytomation, Glostrup, Denmark), as previously described [2, 21].

IFI16 expression was evaluated using standard immunohistochemistry, as already described in a previous study [13]. Images were acquired using an Olympus BX53 fluorescence microscope with CellSens software (Olympus America Inc., Center Valley, PA, USA).

**Statistical analysis**

Data analysis was performed using IBM-SPSS version 13.0 (IBM, Armonk, NY, USA). Mann Whitney \( U \) test or Chi square test were employed to compare variables among subgroups. Binary logistic regression was used to identify possible association between clinical and serological features and the presence of serum IFI16 protein and anti-IFI16 antibody. The significance level was two sided and set at \( p < 0.05 \).

**Results**

**Serum IFI16 protein and anti-IFI16 antibody detection**

As shown in Fig. 1, serum levels of both IFI16 protein and anti-IFI16 antibodies were higher in pSS than in HDs (\( p < 0.05 \) and \( p < 0.0001 \), respectively). According to a cut-off established as the 95th percentile of the control population, positivity for IFI16 protein and for anti-IFI16 was considered for values \( \geq 27 \) ng/ml and \( \geq 113 \) U/ml, respectively. IFI16 was significantly more prevalent in pSS compared to HDs as it was detectable in 14/67 patients (21 %) and in 6/116 HDs (5 %) (\( p < 0.0001 \)). Similarly, a significantly higher prevalence in pSS was confirmed also for anti-IFI16 antibodies that were present in 23/67 pSS patients (34 %) and in 9/182 HDs (5 %) (\( p < 0.0001 \)).

**Clinical and laboratory associations with serum IFI16 protein and anti-IFI16 antibodies**

Table 1 summarizes clinical and serological features in the overall pSS patient population and in patients subdivided according to the presence or absence of serum IFI16/anti-IFI16. We failed to observe any differences among subgroups except for a higher prevalence of rheumatoid factor (RF) in IFI16+ patients. We subsequently evaluated whether IFI16 serum concentration, rather than its presence, could be correlated to any clinical variable. A direct correlation with disease duration (Spearman’s \( \rho = 0.32; \ p = 0.008 \)) and an inverse correlation with age at diagnosis (Spearman’s \( \rho = 0.24; \ p = 0.04 \)), without any association with patients’ age, were observed (data not shown). Interestingly, all IFI16+ patients displayed a disease duration >3 years. No association between

---

**Fig. 1** Expression of interferon gamma-inducible (IFI16) protein (a) and anti-IFI16 antibodies (b) in healthy donors (HD; \( n = 116 \)) and primary Sjögren’s syndrome (pSS) patients (\( n = 67 \)). Bars indicate mean values. Dotted lines mark cut-off levels of positivity determined as the 95th percentile of the control population. \( p \) values were calculated with Mann Whitney \( U \) test.
IFI16 positivity or concentration and disease activity, calculated with the EULAR Sjögren's syndrome disease activity index, was observed. Finally, no correlations between anti-IFI16 antibody positivity or titer and any clinical and/or serological parameters were identified.

Histological evaluation of IFI16 protein at glandular level
The histological analysis of normal MSGs revealed that IFI16 protein was not constitutively expressed by glandular tissue (Fig. 2a). Conversely, few nuclei of glandular epithelial cells were positive for IFI16 staining in NSCS. A cytoplasmic localization of this protein could be only occasionally detected in glandular epithelial cells (Fig. 2b). In this context, IFI16 was also displayed by the nuclei of inflammatory mononuclear cells (Fig. 2b). The scattered or small aggregates of plasma cells, normally present in MSGs or during NSCS, appeared to have nuclei with a lower IFI16 positivity when compared with other inflammatory cells. In contrast, in pSS biopsies intense IFI16-positive nuclei were found in both ductal and acinar epithelial cells. A stronger cytoplasmic staining with respect to normal and NSCS was detected in ductal epithelial cells, while the detection of IFI16 staining in the cytoplasm of acinar epithelial cells was hampered by abundant secretion products (Fig. 2a–c). IFI16 nuclear and cytoplasmic staining was also observed in the inflammatory cells involved in FLS (Fig. 2c). A more detailed analysis of inflammatory infiltrate, according to the distribution of T and B lymphocytes and the presence of GCs, showed a predominance of IFI16 staining in the T- rather than B-cell area containing GC-like structures (Fig. 2e). This particular IFI16 distribution, paralleling B/T cell segregation, was also detectable in the inflammatory follicles of tonsil specimens (Fig. 2d and f). Concerning the nuclear staining for IFI16 in endothelial cells, our results showed that the constitutional expression of IFI16 was more pronounced in pSS FLS peri- and intralesional endothelium compared to normal and NSCS patterns (Fig. 2a–c, inserts).

Correlations between IFI16 protein serum levels and glandular infiltration degree
Taking the aforementioned observations in the serum and in MSGs, we attempted to identify a possible association between circulating IFI16 and histological features. The median focus score (FS), namely the number of foci in 4 mm² of glandular tissue, was 3.5 (range 0–12). We observed that IFI16 concentration was directly correlated with the FS at the time of diagnosis (Spearman’s rho = 0.30; p = 0.02). Furthermore, this association was quantified by binary logistic regression that revealed an odds ratio of 1.4 (95 % confidence interval 1.03 to 1.9; p = 0.03) for the FS. However, since also disease duration and age at diagnosis were found to be correlated with IFI16, we corrected the analysis according to these variables and observed that FS was associated with serum IFI16 independently of disease duration and age at diagnosis.

Table 1: Demographic, clinical and serological characteristics of pSS patients

|                      | All pSS | IFI16 neg | IFI16 pos | p     | anti-IFI16 neg | anti-IFI16 pos | p     |
|----------------------|---------|-----------|-----------|-------|----------------|----------------|-------|
| Patient number (n)   | 67      | 53        | 14        | –     | 44             | 23             | –     |
| Age (years) a        | 59 ± 1  | 60 ± 2    | 55 ± 3    | 0.2   | 60 ± 2         | 56 ± 2         | 0.2   |
| Age at diagnosis (years) a | 49 ± 2 | 50 ± 2    | 45 ± 3    | 0.3   | 51 ± 2         | 46 ± 2         | 0.3   |
| Disease duration (years) a | 9 ± 1   | 9 ± 1     | 10 ± 1    | 0.1   | 9 ± 1          | 10 ± 2         | 0.1   |
| Xerophthalmia        | 92.5    | 94.3      | 85.7      | 0.3   | 86.4           | 82.6           | 0.7   |
| Xerostomia           | 85.1    | 88.7      | 71.4      | 0.2   | 90.9           | 95.7           | 0.6   |
| Salivary gland swelling | 47.8   | 49.1      | 42.9      | 0.8   | 500            | 43.5           | 0.8   |
| Extraglandular manifestations b | 76.1   | 77.3      | 71.4      | 0.7   | 79.5           | 69.5           | 0.4   |
| Leukopenia           | 37.3    | 37.7      | 35.7      | 0.9   | 38.6           | 34.8           | 0.8   |
| Hypergammaglobulinemia | 61.2  | 56.6      | 78.6      | 0.2   | 61.4           | 60.9           | 0.8   |
| Hypocomplementemia   | 26.9    | 22.6      | 42.9      | 0.2   | 25.0           | 30.4           | 0.7   |
| Autoantibodies       |         |           |           |       |                |                |       |
| Neither anti-SSA nor anti-SSB | 16.4  | 17.0      | 14.3      | 0.9   | 18.2           | 13             | 0.7   |
| Anti-SSA only        | 26.9    | 28.3      | 21.4      | 0.7   | 20.5           | 39.1           | 0.1   |
| Anti-SSA and anti-SSB | 56.7   | 54.7      | 64.3      | 0.6   | 61.4           | 47.8           | 0.3   |
| RF ± anti-SSA ± anti-SSB | 68.7  | 60.4      | 100       | 0.003 | 70.5           | 65.2           | 0.8   |

# Values are reported as mean ± standard error of the mean and corresponding p values are calculated with Mann Whitney U test. All other values are reported as percentage of patients and corresponding p values are calculated with chi square test. aPercentage of patients with at least one extraglandular manifestation including articular, pulmonary or esophageal involvement, purpura, Raynaud’s phenomenon and lymphadenopathy. IFI16 interferon gamma-inducible protein 16, neg negative, pos positive, pSS primary Sjögren’s syndrome, RF rheumatoid factor.
(odds ratio = 1.5; 95 % confidence interval 1.02 to 1.9; \( p = 0.04 \)).

Discussion
Several data from animal models and patients highlighted the pathogenic role of the IFN signature in pSS [6, 7], thereby supporting the evaluation of the IFN-inducible gene role as an intriguing issue. In the present study, we confirmed that patients with pSS display circulating IFI16 as well as antibodies reactive against this protein. More interestingly, however, our data appear to suggest that the IFI16 protein may be involved in the development of glandular inflammation occurring in pSS. In fact, unlike normal and NSCS MSGs, a marked expression of this molecule by acinar and ductal epithelial cells as well as infiltrating lymphocytes and peri/intralesional endothelium was found in pSS MSGs.

In recent years, a better understanding of pSS pathogenesis has allowed the identification of salivary gland epithelial cells (SGECs) as active players rather than innocent bystanders in the initiation and perpetuation of the disease [22]. In particular, following IFN ligation to toll-like receptors (TLRs), such as TLR3, SGECs upregulate and mislocalize nuclear proteins in the cytoplasm that are normally segregated from the immune system. These autoantigens, including Ro52 and Ro60, are subsequently

Fig. 2 Expression of IFI16 in MSG and tonsil. Immunohistochemical analysis for IFI16 in MSG with normal architecture (a), NSCS (b), FLS (c) and in tonsil (d). Inserts in a, b and c depict a detail of endothelial cells from the corresponding panel. e, f Double immunofluorescence staining for CD3 (red) and CD20 (green) in FLS (e) and tonsil (f). Insert in e depicts immunofluorescence staining for CD21 (green) and DAPI (blue), representing a GC-like structure in the CD20+ B-cell area of panel e.
released in the extracellular milieu either within exosomes or following SGEC apoptosis [23]. The consequence of these events trigger activation of T lymphocytes and an antigen-specific B-cell recruitment leading to the production of autoantibodies, such as anti-Ro52 and anti-Ro60, key elements of pSS classification criteria [18].

This scenario appears to fit with our findings concerning IFI16 at the glandular level, where the predominant chronic inflammatory process takes place, and anti-IFI16 in the bloodstream. Therefore, it is reasonable to speculate that IFI16 may undergo the same fate as the aforementioned Ro52 and Ro60 nuclear proteins in SGECs. Of interest, in addition, similarly to anti-Ro52 and anti-Ro60 autoantibodies, those against IFI16 are also displayed by some, but not all, pSS patients.

Finally, it is worth mentioning that while some epithelial tissues, including skin, gastrointestinal tract, urogenital tract, and glands and ducts of breast tissues constitutively express IFI16 [8], normal MSGECs do not display the IFI16 protein. This observation underscores that IFI16 overexpression observed in NSCS and, to a greater extent, in pSS results from a “de novo” synthesis of such a protein. The presence of free IFI16 protein in the serum could reflect cell secretion of the protein in the extracellular milieu. The fact that we were able to detect the protein in the serum from only a subgroup of patients is not so surprising, since it is conceivable that the main pathogenic role of IFI16 is exerted at the glandular tissue level. Indeed, autoreactive B lymphocytes in pSS are generated in target tissue where autoantigen release by SGEs is massive. Only when the inflammatory infiltrate is particularly severe can the protein be released in larger amounts in the circulation, as supported by our finding showing a direct correlation between level of serum IFI16 and degree of MSG inflammatory score.

In this setting, our observations that circulating IFI16 levels were associated with RF and inversely correlated with age at disease diagnosis are particularly intriguing. Indeed, although we failed to identify any association with disease activity, this finding appears to fit with the observation that patients diagnosed at a younger age are more likely to have circulating autoantibodies and usually display more severe glandular inflammation [2, 24, 25].

Conclusion
In conclusion, although we are aware that our study displays some limitations due to its retrospective nature and the low number of patients, we believe that our results may shed some light on the role of IFN-inducible genes in pSS pathogenesis. Larger and prospective studies, however, are required to point out a possible application of serum IFI16 protein detection in the current clinical practice.

Abbreviations
BSA: Bovine serum albumin; ELISA: Enzyme-linked immunosorbent assay; FLS: Focal lymphocytic sialadenitis; FS: Focus score; GC: Germinal center; HD: Healthy donor; IFI16: Interferon gamma-inducible protein 16; IFN: Interferon; MGD: Minor salivary gland; NSCS: Nonspecific chronic sialadenitis; PBS: Phosphate-buffered saline; pSS: Primary Sjögren’s syndrome; RF: Rheumatoid factor; SEM: Standard error of the mean; SGEC: Salivary gland epithelial cell; TLR: Toll like receptor.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
AA and VC designed the study, performed experiments on sera, analyzed data and drafted the manuscript; FC participated in the design of the study, performed experiments on histological samples, analyzed data and drafted the manuscript; OB and SC performed sampling, participated in experiments and data analysis and helped to draft the manuscript; EB and RGi enrolled patients, collected clinical data and helped to revise the manuscript; MG participated in the design of the study and helped to draft the manuscript; SL conceived the study, participated in the design of the study and helped to draft the manuscript; RGe conceived the study, participated in the design and coordination of the study and helped to draft the manuscript. All authors read and approved the final manuscript.

Author details
1Rheumatology Unit, Department of Medicine, University of Perugia, Perugia, Italy. 2Virology Unit, Department of Translational Medicine, Novara Medical School, Novara, Italy. 3Rheumatology Unit, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy. 4Viral Pathogenesis Unit, Department of Public Health and Pediatric Sciences, Turin Medical School, Turin, Italy.

Received: 21 May 2015 Accepted: 21 July 2015
Published online: 14 August 2015

References
1. Brito-Zepon R, Ramos-Casals M. Advances in the understanding and treatment of systemic complications in Sjögren’s syndrome; EULAR-SS task force group. Curr Opin Rheumatol. 2014;26:520–7.
2. Garabbi F, Alunno A, Cipriani P, Di Benedetto P, Ruscitti P, Berarducci O, et al. Is minor salivary gland biopsy more than a diagnostic tool in primary Sjögren’s syndrome? Association between clinical, histopathological and molecular features: a retrospective study. Semin Arthritis Rheum. 2014;44:314–24.
3. Chouby D, Moudgil KD. Interferons in autoimmune and inflammatory diseases: regulation and roles. J Interferon Cytokine Res. 2013;31:657–65.
4. González-Navajas JM, Lee J, David M, Rae E. Immunomodulatory functions of type I interferons. Nat Rev Immunol. 2012;12:2125–35.
5. Peck AB, Nguyen CQ. Transcriptome analysis of the interferon-signature defining the autoimmune process of Sjögren’s syndrome. Scand J Immunol. 2012;76:237–45.
6. Nguyen CQ, Peck AB. The interferon-signature of Sjögren’s syndrome: how unique biomarkers can identify underlying inflammatory and immunopathological mechanisms of specific diseases. Front Immunol. 2013;4:142.
7. Nordmark G, Eloanta ML, Ronnblom L. Primary Sjögren’s syndrome and the type I interferon system. Curr Pharm Biotechnol. 2012;13:2054–62.
8. Gargiolo M, Azzimonti B, Pagano M, Palestro G, De Andrea M, Valente G, et al. Immunohistochemical expression analysis of the human interferon-inducible gene IFI16, a member of the HIN200 family, not restricted to hematopoietic cells. J Interferon Cytokine Res. 2002;22:815–21.
9. Unterhözner L, Keating SE, Baran M, Horan KA, Jensen SB, Sharma S, et al. F16 is an innate immune sensor for intracellular DNA. Nat Immunol. 2010;11:1097–1004.
10. Mondini M, Costa S, Sponza S, Gugliesi F, Gargiolo M, Landolfo S. The interferon-inducible HIN-200 gene family in apoptosis and inflammation: implication for autoimmunity. Autoimmunity. 2010;43:226–31.
11. Gugliesi F, De Andrea M, Mondini M, Cappello P, Giovarrelli M, Shoenfeld Y, et al. The proapoptotic activity of the Interferon-inducible gene IFI16 provides new insights into its etiopathogenetic role in autoimmunity. J Autoimmun. 2010;35:114–23.
12. Mondini M, Vidali M, Airò P, De Andrea M, Riboldi P, Meroni PL, et al. Role of the interferon-inducible gene IFI16 in the etiopathogenesis of systemic autoimmune disorders. Ann NY Acad Sci. 2007;1110:47–56.

13. Costa S, Borgogna C, Mondini M, De Andrea M, Meroni PL, Berti E, et al. Redistribution of the nuclear protein IFI16 into the cytoplasm of ultraviolet B-exposed keratinocytes as a mechanism of autoantigen processing. Br J Dermatol. 2011;164:282–90.

14. Bawadekar M, De Andrea M, Gariglio M, Landolfo S. Mislocalization of the interferon inducible protein IFI16 by environmental insults: implications in autoimmunity. Cytokine Growth Factor Rev. 2015;26:213–9.

15. Gugliesi F, Bawadekar M, De Andrea M, Dell'Oste V, Caneparo V, Tincani A, et al. Nuclear DNA sensor IFI16 as circulating protein in autoimmune diseases is a signal of damage that impairs endothelial cells through high-affinity membrane binding. PLoS One. 2013;8:e63045.

16. Costa S, Mondini M, Caneparo V, Afeletra A, Airò P, Bellisai F, et al. Detection of anti-IFI16 antibodies by ELISA: clinical and serological associations in systemic sclerosis. Rheumatology (Oxford). 2011;50:74–81.

17. Caneparo V, Cena T, De Andrea M, Dell’oste V, Stratta P, Quaglia M, et al. Anti-IFI16 antibodies and their relation to disease characteristics in systemic lupus erythematosus. Lupus. 2013;22:607–13.

18. Vitali C, Bombardieri S, Johnsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554–58.

19. Daniels TE. Labial salivary gland biopsy in Sjögren’s syndrome: assessment as a diagnostic criterion in 362 suspected cases. Arthritis Rheum. 1984;27:147–56.

20. Daniels TE, Whitcher JP. Association of patterns of labial salivary gland inflammation with keratoconjunctivitis sicca. Analysis of 618 patients with suspected Sjögren’s syndrome. Arthritis Rheum. 1994;37:869–77.

21. Carubbi F, Cipriani P, Marrelli A, Benedetto P, Ruscetti P, Berardicurti O, et al. Efficacy and safety of rituximab treatment in early primary Sjögren’s syndrome: a prospective, multi-center, follow-up study. Arthritis Res Ther. 2013;15:R172.

22. Barrera MJ, Bahamondes V, Sepulveda D, Quest AF, Castro I, Costés J, et al. Sjögren’s syndrome and the epithelial target: a comprehensive review. J Autoimmun. 2013;42:7–18.

23. Agrawi LA, Kvamstøm M, Brikstad KA, Jonsson R, Skarstein K, Wahren-Herlenius M. Duval epithelial expression of Ro52 correlates with inflammation in salivary glands of patients with primary Sjögren’s syndrome. Clin Exp Immunol. 2014;177:244–52.

24. Gerli R, Muscat C, Giansanti M, Daniell MG, Sciuto M, Gabrielli A, et al. Quantitative assessment of salivary gland inflammatory infiltration in primary Sjögren’s syndrome: its relationship to different demographic, clinical and serological features of the disorder. Br J Rheumatol. 1997;36:69–75.

25. Carubbi F, Alunno A, Cipriani P, Bartolini E, Baldini C, Quartuccio L, et al. A retrospective, multicenter study evaluating the prognostic value of minor salivary gland histology in a large cohort of patients with primary Sjögren’s syndrome. Lupus. 2015;24:315–20.